Objectives: Despite maximally tolerated statin therapy, many patients with high cardiovascular risk, with or without heterozygous familial hypercholesterolemia may require additional low-density lipoprotein cholesterol (LDL-C) reduction. We report pooled alirocumab (ALI) efficacy and safety data from eight Phase 3 trials in 4629 hypercholesterolemia patients, receiving background statin therapy. Material and methods: Studies were pooled by ALI dose and control: ALI 75/150 mg every 2 weeks (Q2W; dose increased to 150 mg Q2W at Week 12 based on Week 8 LDL-C) versus ezetimibe (EZE; Pool 1) or placebo (PBO; Pool 2), and ALI 150 mg Q2W versus PBO (Pool 3). Results: Mean baseline LDL-C was 109 vs. 105 mg/dL (Pool 1), 129 vs. 130 mg/dL (Pool 2) and 126 vs. 125 mg/dL (Pool 3). ALI 75/150 mg Q2W reduced LDL-C by 48.9% (vs. −19.3% EZE) and 48.6% (vs. +4.2% PBO) from baseline to Week 24, and ALI 150 mg Q2W reduced LDL-C by 60.4% (vs. +0.5% PBO; all p b 0.0001). LDL-C reductions were sustained to Week 104. Risk-based LDL-C goals (b70 mg/dL or b 100 mg/dL) were achieved by 78.0%, 75.2%, and 79.0% (Pool 1-3) of ALI-treated patients (vs. 52.4%, 6.4%, and 8.4%, respectively, for controls) at Week 24. Consistent reductions were observed in apolipoprotein B, non-high-density lipoprotein cholesterol, and lipoprotein (a) (p b 0.0001 vs. control). Common adverse events in ALI-treated patients were nasopharyngitis, injection-site reactions, upper respiratory tract infections, and influenza. Conclusions: Alirocumab treatment significantly reduced LDL-C in high cardiovascular risk patients, enabling most to achieve risk-based LDL-C goals.
Introduction
Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for developing and worsening of atherosclerotic cardiovascular disease (ASCVD) [1] . LDL-C reduction is particularly important in people defined as having a high risk of CV events, including those with familial dyslipidemia, severe hypertension, diabetes mellitus, moderate chronic kidney disease (CKD) or a calculated SCORE risk of fatal CV disease of ≥5% [2, 3] . However, many of these patients do not reach LDL-C targets, despite receiving maximally tolerated statin therapy [1, 3, 4] .
Although LDL-C remains the primary focus of lipid-lowering therapy (LLT), other lipoproteins, such as non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein (apo) B, are also recognized as important risk factors. In fact, it has been proposed that these may more accurately reflect the level of circulating atherogenic lipoprotein than LDL-C (calculated using the Friedewald equation) [4] . Lipoprotein(a) [Lp(a)] is an apo B-containing atherogenic lipoprotein that predicts CV risk and is associated with aortic valvular disease independently of LDL-C; it is recognized that statin therapy has little, if any, effect on this parameter.
Alirocumab (a monoclonal antibody that binds to and inhibits proprotein convertase subtilisin/kexin type 9, preventing low-density lipoprotein receptor degradation and thereby increasing LDL-C clearance) has been approved for the treatment of hypercholesterolemia in the USA and the European Union as an adjunct to diet and maximally tolerated statin therapy [5, 6] . In the USA, alirocumab is indicated for use in adults with HeFH or clinical ASCVD who require additional lowering of LDL-C [6] ; in Europe, approval includes adults with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia, with or without other LLTs, in patients unable to reach LDL-C goals with maximum tolerated statin. In Europe, the indication also specifically permits the use of alirocumab as monotherapy or combination therapy with other LLTs in statin-intolerant patients, or for those where statins are contraindicated [5] .
Here, we present a pooled analysis of alirocumab efficacy and safety data from eight ODYSSEY Phase 3 clinical trials of up to 104 weeks in high-risk patients (including people with HeFH, and people with established CVD, or risk equivalents). Each trial was conducted in individuals on background statin therapy. In six of the eight studies, individuals received maximally tolerated statins (accounting for 91% of the total number of individuals included in the pooled dataset), while in the other two studies a fixed dose of background statin was used, either atorvastatin 20-40 mg or rosuvastatin 10-20 mg. In all the individual trials, alirocumab treatment at a dose of 75 or 150 mg every 2 weeks (Q2W) resulted in a significant reduction in LDL-C versus controls in patients at high CV risk with or without HeFH [7] [8] [9] [10] [11] [12] [13] . For the pooled analysis, we report on the effects of alirocumab treatment on LDL-C and other lipid parameters, including non-HDL-C, apo B, and Lp(a).
Methods

Study designs and pooling strategy
This analysis includes data from eight Phase 3 randomized, double-blind, controlled trials ( Fig. 1 ). Methods of the individual trials have been reported previously [8, 9, [11] [12] [13] [14] . Patients were randomized to either alirocumab or control in a 2:1 ratio (1:1 ratio in the OPTIONS I and II studies) and received double-blind study treatment for 24-104 weeks.
For the purposes of the present analysis, efficacy data were analyzed in three pools according to the alirocumab dose and control used in each individual trial. Three trials compared alirocumab 75/150 mg Q2W versus ezetimibe (Pool 1, n = 1130), three trials compared alirocumab 75/150 mg Q2W versus placebo (Pool 2, n = 1051), and two trials compared alirocumab 150 mg Q2W versus placebo (Pool 3, n = 2448) ( Fig. 1 ). In Pools 1 and 2, the alirocumab dose was increased in a blinded fashion from 75 to 150 mg Q2W at Week 12 if Week 8 LDL-C level was ≥70 mg/dL (or ≥70 or ≥100 mg/dL, depending on CV risk, in the OPTIONS I and II studies). Safety data were analyzed in two pools according to control group.
Patients
The FH I, FH II, and HIGH FH studies exclusively recruited patients with HeFH and who were therefore at high CV risk. COMBO I and II recruited non-FH patients at high CV risk (established CHD/CVD or CHD risk equivalents [e.g. CKD or diabetes mellitus with other risk factors]). The other studies recruited both HeFH patients and non-FH patients at high CV risk (as above plus people without documented CHD or CVD but with a 10-year risk of fatal CVD ≥5% [SCORE] in the OPTIONS studies). For study entry, LDL-C at screening had to be ≥70 or 100 mg/dL, depending on CV risk (except in LONG TERM, where LDL-C was ≥70 mg/dL for all patients, and in HIGH FH, where LDL-C had to be ≥160 mg/dL). Eligibility also required all patients to be receiving maximally tolerated statin, with or without other LLT, which was continued throughout the study as background therapy. Exceptions were the OPTIONS I and II trials, which used fixed doses of atorvastatin 20-40 mg and rosuvastatin 10-20 mg, respectively, and COMBO II, in which no other LLT was allowed. Maximally tolerated statin was defined as atorvastatin 40-80 mg, rosuvastatin 20-40 mg, or simvastatin 80 mg (lower doses were allowed with an investigator-approved reason, e.g. intolerance). All studies were conducted in accordance with the ethical principles originating from the Declaration of Helsinki and applicable amendments laid down by the World Medical Assemblies, and the International Conference Harmonization guidelines for Good Clinical Practice. For each participating study site, institutional review board or independent ethics committee approval of the protocols was ascertained and written informed consent was obtained from all patients.
Endpoints and statistical analysis
Efficacy endpoints included the percentage change in LDL-C (calculated using the Friedewald formula), apo B, non-HDL-C, Lp(a), triglycerides, HDL-C, and apo A1 from baseline to Week 12 (before possible dose increase) and Week 24 (primary endpoint in each individual study), and the proportion of patients achieving risk-based LDL-C goals. Data were analyzed using an intention-to-treat approach, including all lipid data regardless of adherence to treatment. An analysis using only on-treatment data was also performed. Least-squares mean lipid values were calculated from a mixed-effects model with repeated measures to account for missing data, as described previously [15] . Adjusted means were calculated for Lp(a) and triglycerides, with missing values calculated by multiple imputation followed by robust regression. Combined estimates were calculated for LDL-C goal achievement, with missing data accounted for by multiple imputation followed by logistic regression. Safety was assessed via reporting of treatment-emergent adverse events (TEAEs) and laboratory values. Adverse events were classed as TEAEs if they were reported from the first dose of study treatment up to the last dose plus 70 days. Descriptive statistics only were used for safety analyses (no formal statistics were planned in the study protocols).
Results
Patients
In total, this analysis included 4629 patients (1130 in Pool 1, 1051 in Pool 2, and 2448 in Pool 3). Demographic and baseline characteristics were similar for the alirocumab and control groups within the study pools (Table 1 ). More patients were male than female, and the majority of patients were white. A history of ASCVD was reported for the majority of patients; Pool 1, 84.5% alirocumab versus 79.5% control; Pool 2, 56.5% versus 56.8%; Pool 3, 75.0% versus 77.0%, and a history of diabetes was reported in 35.4% versus 37.4% in Pool 1, 18.9% versus 20.2% in Pool 2, and 34.7% versus 34.5% in Pool 3, respectively (Table 1 ). Pool 2 had the lowest proportion of patients with diabetes or ASCVD, and this pool had the highest baseline LDL-C values ( Table 1) . A greater proportion of patients in Pool 2 had HeFH (69.9%) as the FH I and FH II studies exclusively recruited patients with this condition (Table 1) . Lower rates of ASCVD, diabetes and higher LDL-C are all reflections of the enrichment in FH patients. Most patients were receiving maximally tolerated statin therapy (91%). In Pool 1, 11% of alirocumab-treated individuals were also receiving additional LLT at study entry (vs. 12% control group) compared with 57% and 28% of alirocumab-treated individuals in Pools 2 and 3 (vs. 62% and 28% in respective control groups). Fixed doses of atorvastatin 20-40 mg and rosuvastatin 10-20 mg were used in OPTIONS I and II, respectively. b In the OPTIONS studies, dose was increased if LDL-C was ≥70 mg/ dL (prior CHD) or ≥100 mg/dL (CHD risk equivalents). CHD, coronary heart disease; HeFH, heterozygous familial hypercholesterolemia; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; Q2W, every 2 weeks. Clinicaltrials.gov identifiers: COMBO II, NCT01644188; OPTIONS I, NCT01730040; OPTIONS II, NCT01730053; FH I, NCT01623115; FH II, NCT01709500; COMBO I, NCT01644175; LONG TERM, NCT01507831; HIGH FH, NCT01617655.
LDL-C reductions
The pooled alirocumab groups demonstrated significantly greater reductions from baseline in LDL-C at Weeks 12 and 24 versus ezetimibe or placebo ( Fig. 2) . At Week 12, before potential alirocumab dose increase in those studies utilizing the dose increase strategy, LDL-C was reduced with alirocumab 75 mg Q2W by 49.2% (vs. 22.3% with ezetimibe) in Pool 1 and 44.5% (vs. an increase of 4.1% with placebo) in Pool 2; the reduction with the 150 mg Q2W dose at Week 12 was 62.6% versus an increase of 1.1% with placebo in pool 3 (all comparisons p b 0.0001; Fig. 2A ). For pools 1 and 2, dose increase to 150 mg Q2W at Week 12 occurred in 18% and 35% of patients, respectively. At Week 24, LDL-C was reduced with alirocumab 75/150 mg Q2W by 48.9% (vs. 19 .3% with ezetimibe, Pool 1) and 48.6% (vs. a 4.2% increase with placebo, Pool 2), and was reduced with alirocumab 150 mg Q2W (Pool 3) by 60.4% (vs. a 0.5% increase with placebo, all comparisons p b 0.0001; Fig. 2B ). LDL-C reductions with alirocumab were observed from Week 4 and were maintained up to 78/104 weeks ( Fig. 3 ). Across the three pools, significantly more patients achieved their risk-based LDL-C goals with alirocumab (75-79% by Week 24) versus ezetimibe (52%) or placebo (6-8%) ( Fig. 4 ).
Changes in other lipid parameters
In addition to the LDL-C reductions, levels of non-HDL-C, apo B, and Lp(a) were all significantly reduced with alirocumab ( Fig. 5 ; p b 0.0001). Significant reductions in triglycerides were observed with alirocumab versus placebo in Pools 2 and 3 (10.3% and 17.0%, respectively, at Week 24; p b 0.0001; Table 2 ). Reductions in triglycerides versus ezetimibe were not significant ( Table 2 , Pool 1). HDL-C and apo A1 levels increased modestly but significantly (p b 0.0001) following alirocumab treatment versus placebo and versus ezetimibe ( Table 2 ).
Safety summary
Overall rates of TEAEs, serious adverse events, deaths, and discontinuations were similar between alirocumab and control groups ( Table 3) . TEAEs occurring more frequently (≥5.0%) with alirocumab versus placebo were nasopharyngitis (12.6% vs. 12.1%), influenza (6.3% vs. 5.4%), diarrhea (5.3% vs. 4.9%), and injection site reaction (7.2% vs. 5.3%); those occurring more frequently with placebo versus alirocumab were upper respiratory tract infection (8.0% vs. 7.0%), back pain (6.0% vs. 5.3%), headache (5.5% vs. 5.1%), and arthralgia (6.5% vs. 5.1%). TEAEs with a higher incidence in the alirocumab versus ezetimibe groups were upper respiratory tract infection (7.7% vs. 6.8%), headache (5.0% vs. 3.6%), hypertension (5.5% vs. 5.2%), and injection site reaction (2.6% vs. 1.1%); those occurring with higher incidence in the ezetimibe versus alirocumab groups were nasopharyngitis (5.2% vs. 4.7%) and dizziness (5.4% vs. 4.8%). In alirocumab-and ezetimibe-treated patients, 0.3% and 0.2% permanently discontinued due to injection site reaction; corresponding numbers for alirocumab versus placebo were 0.2% and 0.3%.
Discussion
This pooled analysis included 4629 high CV risk patients from eight Phase 3 trials whose LDL-C levels were inadequately controlled despite maximally tolerated background statin with or without other LLTs. The majority of patients (73%) had a history of ASCVD, and a large proportion had HeFH (28.1%) or diabetes (31.5%). In this cohort of patients, the addition of alirocumab significantly reduced LDL-C levels versus ezetimibe or placebo controls (48.6-60.4% across the pools at Week 24, p b 0.0001 versus control), and LDL-C reductions were maintained for the duration of treatment, up to 104 weeks. Across all three pools, consistent significant reductions with alirocumab were also observed in atherogenic lipid parameters, non-HDL-C, apo B, and Lp(a), at Week 24. The alirocumab treatment effect on Lp(a) (17.4-25.1% reduction vs. control) contrasted with that of statin therapy, which appears to have had little or no effect on this parameter [16, 17] . Modest reductions in triglycerides and increases in HDL and apo A1 were also seen in alirocumab-treated patients.
In six of the eight studies analyzed, individuals received maximally tolerated statins (accounting for 91% of the total number of individuals included in the pooled dataset). Overall, 58.4% of all participants were tolerant of high-dose statins (defined as atorvastatin 40-80 mg, rosuvastatin 20-40 mg, or simvastatin 80 mg) at study entry and as background therapy throughout the trial period; the remainder received lower doses (as per protocol with an investigator-approved reason, e.g. myalgia). However, baseline data demonstrated a need for further LLT, particularly for those individuals who did not achieve their LDL-C targets or who were unable to tolerate higher doses of statin therapy. In this high CV risk population, baseline mean LDL-C levels for all pools were N105 mg/dL, confirming the extent of the unmet need in these patients, despite statin therapy. Individuals in Pool 2 had the greatest unmet need, with the highest LDL-C levels at study entry (mean 129-130 mg/dL).
Studies in this pooled analysis were grouped by starting dose of alirocumab. Pools 1 and 2 had a lower starting dose of alirocumab (75 mg Q2W) than Pool 3 (alirocumab 150 mg Q2W). In Pools 1 and 2, Week 12 results gave an estimate of the efficacy of the two doses separately, before potential per-protocol dose increase. Significant reductions in LDL-C were observed from as early as 12 weeks; at this point, LDL-C was reduced by 44.5-49.2% from baseline with alirocumab 75 mg Q2W and by 62.6% with 150 mg Q2W. Improvements in other lipid parameters were also observed. At Week 12, the proportion of patients in the placebo-controlled pool who required a dose increase (35%) was higher than for the ezetimibe-controlled pool (18%). This is likely due to the higher proportion of HeFH patients having higher mean baseline LDL-C levels in the placebo-controlled pool.
The benefit of having two starting alirocumab doses is that it allows for flexibility and individualization of therapy based on each patient's LDL-C levels and treatment goals. For example, for those with inadequately controlled LDL-C levels (e.g. ≥160 mg/dL in the HIGH FH study) it may be appropriate to initiate treatment with 150 mg alirocumab Q2W, while those with lower LDL-C levels can be started on a lower dose of 75 mg Q2W, with the potential to increase the dose to 150 mg Q2W if goals are not met.
The pooled alirocumab efficacy data presented is consistent with that observed in other patient populations. Previously, alirocumab has significantly reduced LDL-C levels in studies performed without background statin (45% reduction with alirocumab [n = 126] versus 15% with ezetimibe [n = 125] in the ALTERNATIVE trial [18] , and 47% [n = 52] versus 16% [n = 51], respectively, in the MONO trial [15] ). In addition, overall safety data from the present pooled analysis demonstrated similar tolerability compared with the control groups and previous studies. The increased incidence of injection site reactions is considered to be related to alirocumab treatment, although most events reported have been rated as mild in severity and self-rate limiting [5, 6] . The percentage of alirocumab-treated patients discontinuing due to injection site reactions was very low (≤0.3%).
Statin therapy, with or without other LLT, can reduce the risk of CV disease in high-risk patients, but tolerability and compliance issues may contribute to many patients failing to achieve desired LDL-C levels [19] . In other large scale trials, such as IMPROVE-IT (conducted in patients following acute coronary syndrome), lowering of LDL-C levels by approximately 24% was shown to significantly improve CV outcomes, and reductions below target levels conferred additional benefits [20] . In earlier studies using intensive statin therapy such as PROVE-IT [21] and TNT [22] , LDL-C levels of 62 mg/dL and 77 mg/dL, were achieved with 80 mg atorvastatin. In the present analysis where alirocumab was added to the existing statin regimen (± other LLT), mean LDL-C levels of below the 70 mg/dL were achieved across all pools (Week 24, Pool 1, 54 mg/dL; Pool 2, 65 mg/dL; Pool 3, 51 mg/dL). The alirocumab studies included in this analysis were not designed to prospectively analyze occurrence of CV events, however, the effect of alirocumab on CV events is currently being assessed in the large-scale (n = 18,000 patients) ODYSSEY OUTCOMES trial (NCT01663402) [23] .
Study limitations
The main limitation of this analysis is that it was a post hoc analysis of pooled studies and, as a result of pooling, the patient population covered a broad clinical spectrum, likely resulting in variations in baseline characteristics. However, while data from an individual study provide information about a single study scenario, this pooled analysis of larger numbers of patients accumulated across the studies allows visualization of the data across different trial design elements (including patient population, dose regimen, control arm, and use of background LLTs). In addition to allowing further characterization of the data, the results also confirm the generalizability and consistency of the drug effect in less frequently represented subgroups in these studies. 
Conclusions
In summary, in high CV risk patients on maximally-tolerated statin ± other LLT, alirocumab (75 or 150 mg Q2W) demonstrated significant LDL-C reductions versus controls, ranging from 47% to 60% according to study designs. Mean LDL-C levels below target levels of ≤ 70/ ≤100 mg/dL (dependent on CV risk) were achieved in all pools and significant improvements were seen in non-HDL-C, apo B, Lp(a), and other lipid parameters. Overall safety was comparable with controls, with a higher rate of injection site reactions with alirocumab.
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